Literature DB >> 30539636

Metabolic Signature of Primary Biliary Cholangitis and Its Comparison with Celiac Disease.

Alessia Vignoli1, Beatrice Orlandini2, Leonardo Tenori3,4, Maria Rosa Biagini2, Stefano Milani2, Daniela Renzi2,5, Claudio Luchinat1,4,6, Antonino Salvatore Calabrò2,5.   

Abstract

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by ongoing inflammatory destruction of the interlobular bile ducts, eventually leading to chronic cholestasis and biliary cirrhosis. This study primarily aims to define the metabolomic signature of PBC after comparison with healthy controls (HC). Second, it aims to evaluate the possible metabolic association between PBC and celiac disease (CD), an immune-mediated disorder frequently associated with PBC. Serum and urine samples from 20 PBC, 21 CD, and 19 sex-matched HC subjects were collected. 1H nuclear magnetic resonance (NMR) spectra for all samples were acquired, and multivariate statistics were used to evaluate the differences among the three groups and to provide information about the involved metabolites. The classification accuracies to discriminate PBC and HC groups were 78.9-84.6% for serum and 76.9% for urine. In comparison to HC, PBC patient sera were characterized by altered levels ( p value <0.05) of pyruvate, citrate, glutamate, glutamine, serine, tyrosine, phenylalanine, and lactate. PBC patient urine showed lower levels ( p value <0.05) of trigonelline and hippurate with respect to HC. Furthermore, the NMR metabolomic fingerprint was able to cluster PBC with respect to CD patients, and the classification accuracies in the discriminations between these groups were 81.9-91.7% for serum and 77.7% for urine. Our results show that PBC displays a unique metabolomic fingerprint, which led to speculation about an impaired energy metabolism, probably associated with an altered gut microbiota. PBC and CD showed two distinct metabolic fingerprints. These data could provide clues for the comprehension of the PBC pathogenetic mechanisms and the detection of novel therapeutic targets.

Entities:  

Keywords:  NMR; celiac disease; metabolites; metabolomics; primary biliary cholangitis

Mesh:

Year:  2019        PMID: 30539636     DOI: 10.1021/acs.jproteome.8b00849

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  11 in total

Review 1.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

Review 2.  Trust Your Gut: The Association of Gut Microbiota and Liver Disease.

Authors:  Ridda Manzoor; Weshah Ahmed; Nariman Afify; Mashal Memon; Maryam Yasin; Hamda Memon; Mohammad Rustom; Mohannad Al Akeel; Noora Alhajri
Journal:  Microorganisms       Date:  2022-05-18

Review 3.  Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.

Authors:  Alessia Vignoli; Emanuela Risi; Amelia McCartney; Ilenia Migliaccio; Erica Moretti; Luca Malorni; Claudio Luchinat; Laura Biganzoli; Leonardo Tenori
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 4.  Metabolomics profile in gastrointestinal cancers: Update and future perspectives.

Authors:  Giulia Nannini; Gaia Meoni; Amedeo Amedei; Leonardo Tenori
Journal:  World J Gastroenterol       Date:  2020-05-28       Impact factor: 5.742

5.  Differential Network Analysis Reveals Molecular Determinants Associated with Blood Pressure and Heart Rate in Healthy Subjects.

Authors:  Alessia Vignoli; Leonardo Tenori; Claudio Luchinat; Edoardo Saccenti
Journal:  J Proteome Res       Date:  2020-12-04       Impact factor: 4.466

6.  Analysis of Metabolite and Lipid Association Networks Reveals Molecular Mechanisms Associated with 3-Month Mortality and Poor Functional Outcomes in Patients with Acute Ischemic Stroke after Thrombolytic Treatment with Recombinant Tissue Plasminogen Activator.

Authors:  Cristina Licari; Leonardo Tenori; Betti Giusti; Elena Sticchi; Ada Kura; Rosina De Cario; Domenico Inzitari; Benedetta Piccardi; Mascia Nesi; Cristina Sarti; Francesco Arba; Vanessa Palumbo; Patrizia Nencini; Rossella Marcucci; Anna Maria Gori; Claudio Luchinat; Edoardo Saccenti
Journal:  J Proteome Res       Date:  2021-09-02       Impact factor: 4.466

7.  Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.

Authors:  Gaia Meoni; Leonardo Tenori; Sebastian Schade; Cristina Licari; Chiara Pirazzini; Maria Giulia Bacalini; Paolo Garagnani; Paola Turano; Claudia Trenkwalder; Claudio Franceschi; Brit Mollenhauer; Claudio Luchinat
Journal:  NPJ Parkinsons Dis       Date:  2022-02-08

8.  Exploration of Blood Lipoprotein and Lipid Fraction Profiles in Healthy Subjects through Integrated Univariate, Multivariate, and Network Analysis Reveals Association of Lipase Activity and Cholesterol Esterification with Sex and Age.

Authors:  Yasmijn Balder; Alessia Vignoli; Leonardo Tenori; Claudio Luchinat; Edoardo Saccenti
Journal:  Metabolites       Date:  2021-05-18

9.  Serum Zinc Level and non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Ryo Takata; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Kunihiro Hasegawa; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

10.  Differential Network Analysis Reveals Metabolic Determinants Associated with Mortality in Acute Myocardial Infarction Patients and Suggests Potential Mechanisms Underlying Different Clinical Scores Used To Predict Death.

Authors:  Alessia Vignoli; Leonardo Tenori; Betti Giusti; Serafina Valente; Nazario Carrabba; Daniela Balzi; Alessandro Barchielli; Niccolò Marchionni; Gian Franco Gensini; Rossella Marcucci; Anna Maria Gori; Claudio Luchinat; Edoardo Saccenti
Journal:  J Proteome Res       Date:  2020-01-17       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.